Teaching Lecture: Advances in breast cancer imaging
|
 |
A. Tardivon (France) |
Advances in breast cancer imaging |
Teaching Lecture: How can you tell if your local breast unit is good?
|
|
R.A.E.M. Tollenaar (The Netherlands) |
How can you tell if your local breast unit is good? |
Teaching Lecture: Free margins
|
|
G. Viale (Italy) |
Free margins |
Europa Donna teaching lecture: Impact of lifestyle on breast cancer
|
|
C. La Vecchia (Italy) |
Impact of lifestyle on breast cancer services |
| |
Patient Management Workshop: Implementation of quality control in breast cancer services
|
|
R.E. Mansel (United Kingdom) |
Quality control in breast cancer services |
Keynote symposium: Local regional control
|
|
M. Bollet (France) |
Local relapse - same or different disease? |
|
E. Winer (USA) |
Effects of impact of systemic treatment of local control |
|
E.J.T. Rutgers (The Netherlands) |
What surgery constitutes optimal local control |
Round Table session: Barriers to academic research
|
|
T. Cufer (Slovenia) |
Optimising drug development by removing barriers between academia and industry |
|
P. Poortmans (The Netherlands) |
Barriers to academic research in radiation oncology |
|
E.J.T. Rutgers (The Netherlands) |
Barriers to academic research in surgical oncology |
Debate: This house believes that nodal status should no longer dictate adjuvant chemotherapy
|
|
A. Di Leo (Italy) |
Nodal status should no longer dictate adjuvant chemotherapy |
|
J. Bergh (Sweden) |
Nodal status should no longer dictate adjuvant chemotherapy |
Debate: This house believes that partial breast radiotherapy is ready to enter the clinical practice
|
|
Y. Belkacemi (France) |
Partial RT is ready to enter the clinical practice |
|
A. Kuten (Israel) |
PBI is ready to enter clinical practice |
Clinical science symposium: Is tailored chemotherapy becoming a reality?
|
|
C. Oakman (Italy) |
Can we select patients for adjuvant therapy based on the presence of micro-metastatic disease? |
|
C. Desmedt (Belgium) |
Anthracyclines and topoisomerase II alpha - what is beyond? |
|
H. Bonnefoi (France) |
Predictive signatures for chemosensitivity and new targeted therapies - dream or reality ? |
|
J. Bartlett (United Kingdom) |
Duplication of chromosome 17 CEP predicts for anthracycline benefit: Evidence from an international meta-analysis of 4 adjuvant breast cancers trials for the HER2/TOP2A meta-analysis study group. |
Clinical science symposium: Lobular cancer is different
|
|
P. Poortmans (The Netherlands) |
Special aspects of local treatment for invasive lobular carcinoma |
|
V. Cocquyt (Belgium) |
Risk for metastases and implications for systemic treatment |
|
S. Chia (Canada) |
Outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma: A population based study from British Columbia |
|
C.E. Vitelli (Italy) |
Lobular cancer is different, but its surgical management is changing over time: analysis of an institutional database over a 10-year period |
| |
Clinical science symposium: Stroma and microenvironment
|
|
R. Iggo (France) |
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer |
|
T. Hayashida (Japan) |
HOXB9, a gene overexpressed in breast cancer, induces angiogenesis, invasion, and lung metastasis |
Europa Donna session: Life after breast cancer
|
|
S. Kyriakides (Cyprus) |
Psychological needs after treatment |
|
M. Remie (The Netherlands) |
The importance of rehabilitation |
Europa Donna "Wrap up" session: "Wrap-up" session
|
|
A. Di Leo (Italy) |
Summary from the Clinical Science Symposium Is tailored chemotherapy becoming a reality? |